In two identical phase 3 , double-blind studies ( study 04 , 652 participants ; study 05 , 700 participants ) , outpatients with noncancer pain and opioid-induced constipation were randomly assigned to receive a daily dose of 12.5 or 25 mg of naloxegol or placebo .